Societal CDMO lands NCI packaging deal for anti-tumor capsules following rebrand
In the first deal since it rebranded, Societal CDMO has landed an agreement with the National Cancer Institute’s Division of Cancer Treatment and Diagnosis to manufacture and package ammonium tetrathiomolybdate capsules.
ATTM capsules are believed to have the potential to enhance the activity of platinum-based antitumor agents. The CDMO will provide scalable manufacturing for the production of 100 mg capsules, and carry out a 36-month shelf life study. The project is partially funded with funds from the National Institutes of Health.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.